Hikma Pharmaceuticals


Strong Generics-led finish to 2023

22/02/24 -"Hikma’s H2 23 results exceeded the street’s expectations, with Generics being the lead performer. Even the 2024 guidance was largely in line with the consensus estimates. The results were cheered by ..."

Pages
50
Language
English
Published on
22/02/24
You may also be interested by these reports :
14/04/24
We have removed Novo Nordisk from the Bayer peer group since the Danish obesity franchise company has reached a stellar valuation. This has had a ...

13/04/24
We have removed Novo Nordisk from the Merck peer group since the Danish obesity franchise company has reached a stellar valuation. This has had a ...

11/04/24
The 2023 bottom line was materially below our expectations owing to the slower-than-expected recovery in profitability and higher interest expenses. ...

03/04/24
While AstraZeneca witnessed a phenomenal turnaround in the last decade, the share price has been quiet in the last two years as sentiment has been ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO